Results From the Dapivirine Vaginal Ring (DREAM) HIV Prevention Study
The DREAM study aimed to evaluate safety, adherence, and HIV-1 incidence in participants using the dapivirine vaginal ring (DVR).
Educational Objectives
Educational Aim:
The aim of this article is to provide information
on the DREAM study, which aimed to
evaluate safety, adherence, and HIV-1 incidence in participants using the
dapivirine vaginal ring (DVR) in open-label use.
Editor's comments:
The non-profit International Partnership for
Microbicides (IPM) announced on 11 March 2022 that the monthly dapivirine
vaginal ring received regulatory approval from the South African Health
Products Regulatory Authority (SAHPRA) for its use by women ages 18 and older
to reduce their HIV risk. This marks a major milestone that brings the first
long-acting woman-initiated prevention product for possible broader access to
the SA female population.
Educational Outcomes:
Upon completion of this module practitioners
should have a better understanding of dapivirine ring trials and outcomes; including
the DREAM
study which was an open-label extension of The Ring Study. The observed low
HIV-1 incidence and improved adherence observed in DREAM support the hypothesis
that increased efficacy due to improved adherence occurs when women know the
demonstrated safety and efficacy of the DVR.
Instructions for this Module
- Read the supplied reading material and complete the quiz that follows;
- You have three attempts to pass the quiz;
- The pass grade is 70%;
- You need to pass the quiz to claim your CPD certificate;
- Please click on the CPD certificate link below to claim your CPD certificate and to update your CPD Manager.
If you need any assistance to complete this module, please Contact us